The CDC will replace Covid-19 data reporting once the federal fitness emergency ends next week, the company announced Friday.
As of May 11, the CDC will no longer report the total weekly number of Covid instances or degrees of network transmission, the firm said. reports of asymptomatic practices and instances, the firm said.
Unlock this story right away and sign up for more than 167,800 biopharmaceutical professionals to read Endpoints daily, and it’s free.
The strategy of R
Dr. Lindsay Rosenwald founded Fortress Biotech (FBIO), looking for an opportunity to fill a gap in drug development while generating returns for investors. After decades of successfully founding and promoting biopharmaceutical companies, he came out of retirement with an idea for a new business. Style in the field of life sciences. The style would take the most productive attributes of a royalty, personal justice, and classic biopharma business to concentrate primarily on clinical progression and commercialization, without the threat of extensive studies and preclinical progression. He combined this into Fortress Bio.
When Vertex intends to target a target, executives have been known to spend heavily on experimental products.
This enthusiastic spirit became fully visible in 2022 when biotech transferred more than $250 million in money for Entrada Therapeutics’ DM1 preclinical treatment.
Unlock this item and others by subscribing to one of our paid plans.
A federal jury in favor of Gilead on Tuesday in a protracted patent war over the use of its HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP).
While Truvada and Descovy were first approved for HIV treatment in 2004 and 2016, respectively, they all gained approvals years later in the preventive framework. transparent contributions and the unfounded denial of the validity of CDC patents” in the progression of its PrEP franchise.
Unlock this story right away and sign up for more than 167,800 biopharmaceutical professionals to read Endpoints daily, and it’s free.
In December, AbbVie won a fourth indication for Vraylar as an adjunct to antidepressants for the treatment of primary depressive disorder, and has now launched an advertising crusade to help.
The crusade includes a TV ad with a purple, teal “V” filling the screen, emerging from the rear as a woman lifts a garage door and talks about getting a “lift” for her antidepressant with the addition of Vraylar. According to an AbbVie spokesperson, the work was filed in April and includes television, online video, social media and research.
Unlock this story right away and sign up for more than 167,800 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Tarsus Pharmaceuticals has a message for patients who believe they have Demodex blepharitis or eyes irritated by the tiny dust mites: “Don’t panic. Get yourself checked.
The new unbranded crusade was unveiled Monday, just months before the FDA issued a ruling on the Tarsus remedy, an edition of the non-unusual veterinary drug lotilaner that is used to prevent tick and flea infestations in dogs. An approval would mark the first time the drug has been legal for humans. While Tarsus’ latest crusade, “Look at the Eyelids,” focused on eye care professionals, this one aims to teach patients about the symptoms and diagnosis of Demodex blepharitis.
Unlock this story right away and sign up for more than 167,800 biopharmaceutical professionals to read Endpoints daily, and it’s free.
A new study letter published today in JAMA questions whether they deserve continued incentives for orphan drugs given the increase in approvals in rare disease fields and so many subsequent blockbusters.
Of the 315 drugs reviewed between 2008 and 2016, 83 (26%) were first indicated for designated orphan conditions. Five-year average net sales were $719 million for designated orphan drugs and $812 million for non-orphan drugs. West Virginia and the Harvard researchers said their knowledge showed how “drugs originally approved for a designated orphan condition were as lucrative to their brands as drugs evolved for more non-unusual conditions. “
Unlock this story right away and sign up for more than 167,800 biopharmaceutical professionals to read Endpoints daily, and it’s free.
AstraZeneca said Tuesday that the FDA approved AstraZeneca’s Farxiga (dapagliflozin), an oral SGLT2 inhibitor, for label extension to threatened cardiovascular death, hospitalization for center failure and urgent visits for center failure in adults with center failure.
The company said the FDA approved the extension based on data from a phase III trial that showed the drug met the number one endpoint, statistically and clinically significant early relief in cardiovascular mortality or worsening of center failure in patients with certain center types. fault.
Unlock this story right away and sign up for more than 167,800 biopharmaceutical professionals to read Endpoints daily, and it’s free.
After sending warning letters to several foreign drug brands related to contamination issues, the FDA issued new guidance for the prompt implementation of testing for glycerin and other chemicals with the destructive contaminants diethylene glycol (DEG) and ethylene glycol (EG).
The FDA’s new 11-page guidance alerts manufacturers, suppliers and others to health hazards related to glycerin and other drug parts that may become infected with DEG or EG.
Unlock this story right away and sign up for more than 167,800 biopharmaceutical professionals to read Endpoints daily, and it’s free.
© Endpoints 2023 News
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.